📰 Financial TimesFinancial TimesCodex · 实盘不做把握 7/10🔁 +1 同一事件
北京时间·🕒 发布 02:12:05时区推断·⟳ 抓取 02:44:19·⚡ 决策 07-17 02:51:27 +7m08s·102.9 天前
达索系统洽购ArisGlobal，潜在交易估值约20亿美元
潜在收购金额约20亿美元，相对达索系统约245亿欧元市值不算小，但目前只是谈判，交易并非确定。
📄 原文Financial Times↗ 原文
Dassault Systèmes in talks to buy drug trial software company for about $2bn French conglomerate Dassault Systèmes is i…
不做 达索系统（DSY.FR）
买方并购谈判未定，估值约10倍收入且缺少增厚量化，方向偏混合，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-16 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 潜在收购金额约20亿美元，相对达索系统约245亿欧元市值不算小，但目前只是谈判，交易并非确定。
- ArisGlobal年收入约2亿美元，估值约10倍收入，短线更可能被市场解读为高价扩张而非明确增厚。
- ArisGlobal约一半收入来自AI相关服务，但缺少利润、协同和融资结构信息，无法量化对达索系统EPS或现金流的正向贡献。
主要风险
- 若正式公告价格低于传闻、协同明确且融资压力小，判断可能转向中性偏多。
- 达索系统今年已下跌逾20%，但这不是并购利好的交易理由。
反向证据
- 做多前查反向 · 来源 source_article · 日期 2026-07-16 · 影响 weakens
交易未最终达成，且约20亿美元对应ArisGlobal约2亿美元收入，买方短线正向增厚不清晰。
检索:Dassault Systèmes ArisGlobal acquisition $2bn revenue valuation talks not certain 原文 ↗
原文全文
展开原文 · 2,393 字
Dassault Systèmes in talks to buy drug trial software company for about $2bn
French conglomerate Dassault Systèmes is in talks to buy drug trial software maker ArisGlobal from Nordic Capital for about $2bn, in what would represent the latest successful exit for the Swedish private equity group.
The potential deal would extend Dassault’s push into software used in life sciences and would rank as its second-biggest acquisition behind its $5.8bn takeover of clinical trial software group Medidata Solutions in 2019.
Talks between the parties are ongoing over a deal valuing Aris at roughly $2bn, but a transaction is not a foregone conclusion and talks could fall apart, according to people familiar with the matter. Dassault and Nordic declined to comment. Aris did not immediately respond to a request for comment.
Dassault is listed on Euronext Paris but remains controlled by the Dassault industrialist family, whose assent would be critical to the company pressing ahead with the deal, said the people.
Dassault Systèmes, which was spun out of aerospace company Dassault Aviation in 1981, has a market capitalisation of about €24.5bn. Its shares have fallen more than 20 per cent this year.
Swedish buyout group Nordic, which has €39bn of assets under management, has been trying to engineer an exit from Aris in recent months. Last year, Nordic was part of a consortium that sold clinical trial software maker Clario to Thermo Fisher for $9.4bn.
Nordic acquired a majority stake in the US-based ArisGlobal in 2019, boosting its ownership by buying an additional stake from the company’s founding family in 2021. ArisGlobal generates about $200mn in annual revenues, with roughly half of its sales coming from AI-related services.
ArisGlobal has nearly 1,300 employees and sells software to life sciences companies that assists with areas such as drug safety, clinical development and regulatory compliance.
Nordic has further expanded ArisGlobal’s range of services via a pair of acquisitions in 2023.
Nordic is raising another buyout fund, targeting roughly €10bn. As of September last year, it had raised an initial €5bn.
Private equity groups are under pressure from their backers to sell assets in order to distribute cash. Software companies have faced increasing challenges in generating interest for sales, although groups that offer industry-specific services have fared better.
French conglomerate Dassault Systèmes is in talks to buy drug trial software maker ArisGlobal from Nordic Capital for about $2bn, in what would represent the latest successful exit for the Swedish private equity group.
The potential deal would extend Dassault’s push into software used in life sciences and would rank as its second-biggest acquisition behind its $5.8bn takeover of clinical trial software group Medidata Solutions in 2019.
Talks between the parties are ongoing over a deal valuing Aris at roughly $2bn, but a transaction is not a foregone conclusion and talks could fall apart, according to people familiar with the matter. Dassault and Nordic declined to comment. Aris did not immediately respond to a request for comment.
Dassault is listed on Euronext Paris but remains controlled by the Dassault industrialist family, whose assent would be critical to the company pressing ahead with the deal, said the people.
Dassault Systèmes, which was spun out of aerospace company Dassault Aviation in 1981, has a market capitalisation of about €24.5bn. Its shares have fallen more than 20 per cent this year.
Swedish buyout group Nordic, which has €39bn of assets under management, has been trying to engineer an exit from Aris in recent months. Last year, Nordic was part of a consortium that sold clinical trial software maker Clario to Thermo Fisher for $9.4bn.
Nordic acquired a majority stake in the US-based ArisGlobal in 2019, boosting its ownership by buying an additional stake from the company’s founding family in 2021. ArisGlobal generates about $200mn in annual revenues, with roughly half of its sales coming from AI-related services.
ArisGlobal has nearly 1,300 employees and sells software to life sciences companies that assists with areas such as drug safety, clinical development and regulatory compliance.
Nordic has further expanded ArisGlobal’s range of services via a pair of acquisitions in 2023.
Nordic is raising another buyout fund, targeting roughly €10bn. As of September last year, it had raised an initial €5bn.
Private equity groups are under pressure from their backers to sell assets in order to distribute cash. Software companies have faced increasing challenges in generating interest for sales, although groups that offer industry-specific services have fared better.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。